REVIEW article
Front. Physiol.
Sec. Environmental, Aviation and Space Physiology
Volume 16 - 2025 | doi: 10.3389/fphys.2025.1614098
Advances in Stem Cell-Based Therapeutics for Acute High-Altitude Illness: Research Progress and Prospects
Provisionally accepted
- 1General Hospital of the Chinese People's Liberation Army Western Theater, Chengdu, China
- 2People's Liberation Army Joint Logistics Support Force 940th Hospital, Lanzhou, Gansu Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Acute high-altitude illness (AHAI), triggered by hypobaric hypoxia following rapid ascent to high elevations, induces complex pathophysiological responses that may be 4 life-threatening. Recent advances in regenerative medicine have highlighted the therapeutic potential of stem cells in mitigating hypoxia-induced damage. Among them, Mesenchymal stem cells (MSCs), the most extensively investigated, exert therapeutic efficacy through immunomodulation, attenuation of oxidative stress, and enhancement of tissue repair mechanisms. Their paracrine signaling profile facilitates angiogenesis and stabilization of the hypoxic microenvironment. Neural stem cells (NSCs) exhibit robust proliferation and differentiation under hypoxic conditions, offering a novel avenue for the treatment of high-altitude cerebral pathology. Additionally, induced pluripotent stem cells (iPSCs), with their pluripotency and patient-specific derivation, present significant promise for personalized, cell-based interventions. Experimental studies demonstrate that these stem cell types modulate the hypoxic milieu via secretion of cytokines, remodeling of the immune microenvironment, and promotion of neovascularization. Nonetheless, several translational challenges persist, including suboptimal homing efficiency, potential immunogenicity, and uncertain long-term safety profiles in high-altitude settings.Future research should prioritize elucidation of stem cell behavior in hypobaric hypoxia, optimization of delivery systems, and establishment of standardized therapeutic protocols. Rigorous clinical validation through evidence-based approaches will be essential to substantiate safety and efficacy. With continued advances in stem cell biology and translational techniques, stem cell-based therapy is poised to emerge as a viable strategy for the prevention and management of AHAI, provided that its clinical deployment is underpinned by robust scientific evidence.
Keywords: Acute high-altitude illness, Mesenchymal Stem Cells, Neural Stem Cells, Induced Pluripotent Stem Cells, Hypoxia Adaptation
Received: 18 Apr 2025; Accepted: 22 Jul 2025.
Copyright: © 2025 Dou, Li, Li, Chen, Yang, Fan and Yao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Hao Yao, General Hospital of the Chinese People's Liberation Army Western Theater, Chengdu, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.